Principal Investigator: Duane Mitchell, MD, Ph.D. (University of Florida)
This article is in relationship to the post – A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors
ACTION is an innovative immunotherapy trial for the treatment of high-grade gliomas (HGG) in children. Pediatric brain tumors like HGG are now the leading cause of cancer-related deaths in children in the United States due to the advances in the treatment of more common hematologic malignancies. Current treatments such as surgical removal of the tumor, radiation, and chemotherapy can cure many patients with other types of brain tumors; however, the prognosis for children with high-grade gliomas (HGGs) remains poor.
It is believed that the body’s immune system protects the by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. But in most patients with high-grade gliomas (HGGs), T-cells are not stimulated enough to kill the tumor. In this trial, the patient’s tumor will be used to make a vaccine which will hopefully stimulate the T-cells to kill the tumor cells, while leaving the normal cells alone.